Prevalence of antibiotic resistance in clinical isolates of Mycobacterium kansasii: a systematic review and meta-analysis

ABSTRACT

Introduction

The prevalence of diseases caused by non-tuberculous mycobacteria (NTM), including M. kansasii, is increasing, necessitating further information to guide prevention, control, and treatment strategies.

Areas covered

A comprehensive analysis of articles published until February 2023 was conducted on PubMed, Web of Science, and Scopus databases to investigate antibiotic resistance in M. kansasii species. Stata software version 17 was employed for all analyses.

Expert opinion

A total of 1647 articles were obtained through database search. After removing duplicates and unrelated studies, 17 cross-sectional studies that examined the breakpoints proposed by CLSI were included. The rates of resistance of M. kansasii to various antibiotics were as follows: clarithromycin (0%), rifampin (1%), amikacin (0%), ciprofloxacin (14%), linezolid (0%), moxifloxacin (0%), rifabutin (1%), doxycycline (96%), and SXT (49%). Our findings underscore the importance of managing and monitoring the use of these antibiotics, as well as the need for further studies to elucidate the exact mechanism of M. kansasii resistance to these antibiotics.

KEYWORDS:

• M. kansasii
• antibiotic resistance
• Stata
• CLSI
• prevalence

Article highlights

• Mycobacterium kansasii can cause a severe pulmonary disease that resembles tuberculosis.

• The currently recommended treatment for M. kansasii involves a combination of isoniazid, rifampin, and a third agent.

• If the bacterium shows resistance to rifampin, alternative drugs can be used against M. kansasii.

• Our findings indicate that primary treatment with clarithromycin and rifampin is effective.

• Our results showed the high levels of resistance for doxycycline, ciprofloxacin, and SXT.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Ethics statement

This article (Ethics Approval ID: IR.IUMS.REC.1402.349) was approved by the ethics committee in Iran University of Medical Sciences (Tehran, Iran).

Data availability statement

All the data in this review are included in the manuscript.

Author contribution statement

Conceptualization: Negar Narimisa. Methodology: Negar Narimisa. Data curation: Forough Goodarzi and, Narjess Bostanghadiri. Writing- Original draft: Negar Narimisa. Visualization and Investigation: Negar Narimisa, and Faramarz Masjedian Jazi. Supervision: Faramarz Masjedian Jazi. Writing- Reviewing and Editing: All authors read and approved the final manuscript.

Supplementary material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/14787210.2024.2313051

Additional information

Funding

This study was financially supported (Ethics Approval ID: IR.IUMS.REC.1402.349) by Iran University of Medical Sciences (Tehran, Iran) and Iran University of Medical Sciences (Tehran, Iran) by a research grant [No.26973].